viernes, 1 de septiembre de 2017

Clinical Trials Update from NCI, August 30, 2017

Clinical Trials Update from NCI, August 30, 2017

National Cancer Institute banner

Clinical Trials Update from NCI, August 30, 2017

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
DNA replication graphic 

FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with metastatic colorectal cancer whose tumors have alterations that affect DNA repair. In the phase 2 trial that led to the accelerated approval, 28% of patients treated with nivolumab experienced an objective response.
Image of metastatic melanoma cells 

Results of an early-phase trial showed that a treatment vaccine personalized to a specific patient’s cancer generated a robust immune response against the cancer and may have helped to prevent it from returning.
Exterior image of NIH Clinical Center 

This recently published page discusses the role of the NIH Clinical Center in cancer research. NCI researchers conduct numerous clinical trials at NIH’s research hospital in Bethesda, Maryland, every year to improve cancer treatment, screening, and diagnosis.

Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
Clinical Trials Information for Patients and Caregivers

Learn how scientific review by experts helps ensure the safety of people who take part in clinical trials.

Most clinical trials run as planned from beginning to end, but sometimes trials are stopped early. Learn the reasons why.
NCI-Supported Clinical Trials that Are Recruiting Patients 

This phase 2 trial studies the side effects and how well pembrolizumab, capecitabine, and oxaliplatin work in treating patients with biliary tract cancer that has spread to other places in the body and cannot be removed by surgery.

This phase 2 trial studies how well fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) works in imaging patients with prostate cancer that is high risk or has returned after a period of improvement. Fluorine F 18 DCFPyL is a radioactive tracer compound that targets the prostate-specific membrane antigen.

This phase 2 trial will assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL patients treated with PT2385.

No hay comentarios:

Publicar un comentario